MedPath

Pasireotide

Generic Name
Pasireotide
Brand Names
Signifor
Drug Type
Small Molecule
Chemical Formula
C58H66N10O9
CAS Number
396091-73-9
Unique Ingredient Identifier
98H1T17066
Background

Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.

Indication

For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.

Associated Conditions
Acromegaly, Cushing's Disease
Clinical Trials
Related News

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Phase 2
Terminated
Conditions
Castrate Resistant Prostate Cancer
Prostate Cancer
Chemotherapy Naive Prostate Cancer
Interventions
Other: Laboratory biomarker analysis
First Posted Date
2011-03-11
Last Posted Date
2025-04-30
Lead Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Target Recruit Count
6
Registration Number
NCT01313559
Locations
🇺🇸

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

🇺🇸

Yale Cancer Center, New Haven, Connecticut, United States

Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.

Phase 2
Completed
Conditions
Non-functioning Pituitary Adenoma
Interventions
First Posted Date
2011-01-26
Last Posted Date
2019-04-26
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
20
Registration Number
NCT01283542
Locations
🇧🇷

Novartis Investigative Site, Sao Paulo, SP, Brazil

Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer

Phase 2
Completed
Conditions
Thyroid Cancer
Interventions
First Posted Date
2011-01-05
Last Posted Date
2021-02-17
Lead Sponsor
Emory University
Target Recruit Count
42
Registration Number
NCT01270321
Locations
🇺🇸

Emory University Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

🇺🇸

Emory University Hospital Midtown, Atlanta, Georgia, United States

Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

Phase 1
Completed
Conditions
Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
Interventions
First Posted Date
2010-12-20
Last Posted Date
2020-12-21
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
36
Registration Number
NCT01263353
Locations
🇩🇪

Novartis Investigative Site, Muenster, Germany

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

Phase 2
Completed
Conditions
Neuroendocrine Tumors
Carcinoid Tumors
Interventions
First Posted Date
2010-12-03
Last Posted Date
2023-03-06
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
29
Registration Number
NCT01253161
Locations
🇺🇸

Stanford Cancer Institute, Stanford, California, United States

🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

Phase 2
Completed
Conditions
Uveal Melanoma
Interventions
First Posted Date
2010-12-02
Last Posted Date
2017-08-01
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
14
Registration Number
NCT01252251
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus

Phase 2
Withdrawn
Conditions
Multiple Myeloma
Interventions
First Posted Date
2010-11-04
Last Posted Date
2013-01-10
Lead Sponsor
Milton S. Hershey Medical Center
Registration Number
NCT01234974
Locations
🇺🇸

Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

Phase 3
Completed
Conditions
Acromegaly
Interventions
First Posted Date
2010-06-04
Last Posted Date
2018-04-05
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
198
Registration Number
NCT01137682
Locations
🇺🇸

Oregon Health & Science University, Portland, Oregon, United States

🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

🇺🇸

Swedish Neuroscience Institute 550 17th Avenue, Suite 500, Seattle, Washington, United States

and more 2 locations

Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers

Phase 2
Completed
Conditions
Hyperglycemia
Interventions
First Posted Date
2010-05-21
Last Posted Date
2014-12-25
Lead Sponsor
Robert R. Henry, MD
Target Recruit Count
45
Registration Number
NCT01128192
Locations
🇺🇸

CMR Center for Metabolic Research VASDHS, San Diego, California, United States

Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess

Phase 3
Completed
Conditions
Pancreatic Cancer
Interventions
Other: placebo
First Posted Date
2009-10-14
Last Posted Date
2016-02-01
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
439
Registration Number
NCT00994110
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy